Erika Hamilton, Chief Development Officer, Late Phase & Director, Breast Cancer Research Program at Sarah Cannon Research Institute, shared a post on LinkedIn:
“Don’t miss Dr. Hans Lee from Sarah Cannon Research Institute presenting today in the plasma cell dyscrasia oral session!
LINKER-AL2 trial of linvoseltamab in patients with relapsed/refractory light chain hashtag#amyloidosis
S100a
3:09-3:21pm (entire oral session is 2:45-5:45pm)”
Other articles featuring Erika Hamilton on OncoDaily.